Journal of Clinical Oncology

I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).

Journal of Clinical Oncology

Amy Jo Chien, Rita A. Mukhtar, Karthik Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Christos Vaklavas, Anthony D. Elias, Mei Wei, Matthew P. Goetz, Laura van 't Veer, Silver Alkhafaji, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman

ATHENA: A phase 1/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced/recurrent hepatocellular carcinoma (HCC).

Journal of Clinical Oncology

Ashley Hamilton, Robin Kate Kelley, Daneng Li, Ignacio Melero Bermejo, Ghassan K. Abou-Alfa, Olatunji B. Alese, Raed Moh'd Taiseer Al-Rajabi, Hani M. Babiker, Mitesh Borad, Farshid Dayyani, Martin Gutierrez, Jung Yong Hong, Lionel Aurelien Kankeu Fonkoua, Thomas Benjamin Karasic, Adel Kardosh, Bridget P. Keenan, Anne M. Noonan, Anwaar Saeed, Attilio Bondanza, John Stone

A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM).

Journal of Clinical Oncology

Siqing Fu, Sarina A. Piha-Paul, Shivani Singh, Jing Peng, Bridget P. Keenan, Jay M. Mei, Kevin Lynch, Ling Li, Ming Song, Xiaojing (Amily) Zhang

CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.

Journal of Clinical Oncology

Gregory P. Botta, Ronan Joseph Kelly, Zhaohui Jin, Hong Ma, Geoffrey Yuyat Ku, Dan Zhao, Rutika Mehta, Julia C. Carnevale, Gloria Sierra, Jie JIA, Raffaele Baffa, Zhonghai Li, Dae Won Kim, Harry H. Yoon

The cognitive load of inpatient consults involving immune-related adverse events.

Journal of Clinical Oncology

Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Journal of Clinical Oncology

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).

Journal of Clinical Oncology

Catherine Choy Smith, Pankit Vachhani, Guillermo Garcia-Manero, Nicole Renee Grieselhuber, Guru Subramanian Guru Murthy, Astha Bhatia, Jatinder Arora, Hooman Izadi, Anthony Fiorino, Raajit Rampal

Should I stay, or should I go? Factors associated with intent to leave academic oncology.

Journal of Clinical Oncology

Ana I. Velazquez Manana, Bismarck Odei, Narjust Florez, Sankalp Pandya, Valerie M Dandar, Dame Idossa, Bridget P. Keenan, Katherine Van Loon, Fumiko Chino

Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.

Journal of Clinical Oncology

Maira Soto, Erin L Filbert, Hai Yang, Li Zhang, Stephanie Starzinski, Alec Starzinski, Alexander Cheung, Tony Li, Frank J. Hsu, Andrew H. Ko, Lawrence Fong, Bridget P Keenan

Phase II trial of durvalumab (MEDI4736) with/without tremelimumab for advanced hepatocellular carcinoma after palliative hypofractionated radiotherapy.

Journal of Clinical Oncology

Luchia Andemicael, Hewitt Chang, Moshiur Mekhail Anwar, Kelly Bauer, John Gordan, Jamese Johnson, Bridget P Keenan, Alan P. Venook, Chia-Ching Jackie Wang, Karen Zhang, Lawrence Fong, Robin Kate Kelley, Mary Uan-Sian Feng

Pages